uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Downregulation of bradykinin B2 receptor in human fibroblasts during prolonged agonist exposure
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Ludwig Institute for Cancer Research.
Show others and affiliations
2003 (English)In: American Journal of Physiology. Heart and Circulatory Physiology, ISSN 0363-6135, E-ISSN 1522-1539, Vol. 284, no 6, H1909-1916 p.Article in journal (Refereed) Published
Abstract [en]

Sustained activation of G protein-coupled receptors results in an attenuation of cellular responses, a phenomenon termed desensitization. Whereas mechanisms for rapid desensitization of ligand-receptor-G protein-effector systems are relatively well characterized, much less is known about long-term adaptation processes that occur in the continuous presence of an agonist. Here we have studied the fate of endogenously expressed bradykinin B(2) receptors on human fibroblasts during prolonged agonist treatment. Stimulation with bradykinin for up to 24 h resulted in a 50% reduction of surface binding sites that was paralleled by a similar decrease of total B(2) receptor protein followed by Western blotting using monoclonal antibodies to the B(2) receptor. Whereas B(2) receptor mRNA levels did not change during 24 h of agonist treatment, B(2) receptor de novo synthesis was attenuated by 35-50%, indicating translational control of B(2) receptor levels. Furthermore, the half-life of B(2) receptor protein was shortened by 20-40% as shown by (35)S-labeled pulse-chase and immunoprecipitation experiments. This study demonstrates that bradykinin B(2) receptor expression during long-term agonist treatment is primarily regulated on the (post)translational level, i.e., by attenuation of de novo synthesis and by reduction of receptor stability.

Place, publisher, year, edition, pages
2003. Vol. 284, no 6, H1909-1916 p.
Keyword [en]
Antibodies; Monoclonal/diagnostic use, Blotting; Northern, Blotting; Western, Bradykinin/pharmacology, Cells; Cultured, Down-Regulation/*drug effects, Fibroblasts/metabolism, Half-Life, Humans, Protein Processing; Post-Translational/physiology, RNA; Messenger/biosynthesis/genetics, Radioligand Assay, Receptor; Bradykinin B2, Receptors; Bradykinin/*agonists, Stimulation; Chemical, Transcription; Genetic/drug effects
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-10484DOI: 10.1152/ajpheart.00034.2003PubMedID: 12742822OAI: oai:DiVA.org:uu-10484DiVA: diva2:38252
Available from: 2007-03-27 Created: 2007-03-27 Last updated: 2017-12-11Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12742822&dopt=Citation

Authority records BETA

Micke, Patrick

Search in DiVA

By author/editor
Micke, Patrick
By organisation
Ludwig Institute for Cancer Research
In the same journal
American Journal of Physiology. Heart and Circulatory Physiology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 631 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf